Similarly, the role of TKIs in the treatment of advanced/metastatic paraganglioma and pheochromocytoma is encouraging, with evidence of a patient harboring an SDHB variant responding to sunitinib-based therapy (O'Kane et al., 2019). This evidence concerns the gene SDHB and hereditary pheochromocytoma-paraganglioma.